News

4SC AG – Company Update

Planegg-Martinsried, Germany, 20 December 2023 – 4SC AG (4SC,…

Poolbeg Pharma plc – Positive Outputs from Lab-Based Analysis of RSV Drug Candidates Identified Using AI

RSV drug candidates with the highest probability of success prioritised 20…

Vicore Appoints Leading Respiratory Medicine Developer Dr. Bertil Lindmark MD, PhD, as Chief Medical Officer

Vicore continues to strengthen its leadership in idiopathic…

Industry Veteran Abbas Hussain Appointed as Chair of Asceneuron

• Further strengthening of leadership team following the appointment…

Acesion Pharma announces Nature Medicine publication of clinical results in Atrial Fibrillation

AP30663 achieved proof of mechanism with first-in-class SK channel…

Engimmune Therapeutics strikes ‘fast-forward’ micro-fluidics collaboration with Swiss innovator CSEM

Collaboration with CSEM will speed up identification of suitable…

Astraveus appoints Dr. Lars Henrik Peeck as Chief Business Development Officer

Paris, France, 12 December 2023 – Astraveus SAS (“Astraveus”…

Poolbeg Pharma – POLB 001 Data Presented at ASH

11 December 2023 - Poolbeg Pharma (AIM: POLB, OTCQB: POLBF,…

Updated clinical safety and efficacy data for iOnctura’s roginolisib presented at ESMO Immuno-Oncology Congress 2023

Updated safety and clinical efficacy data presented at leading…

We’d love to hear from you

For more information about Optimum Strategic Communications, please get in touch.

© Optimum Strategic Communications.